The effectiveness of Clostridium botulinum toxin A (Dysport~R, AbobotulinumtoxinA) in the management of temporomandibular dysfunction (TMD) and a small number of other maxillofacial conditions; an open cohort study

摘要

Aim: To examine the effectiveness of Botulinum Toxin Type A (Dysport~R) in treating TMD and a small number of other maxillofacial conditions in our department. The secondary aim was to identify any predictors of outcome. Methods: A retrospective open cohort study1; data abstraction from 38 case files. Results: The effectiveness of Dysport~R in treating TMD lies between 60% and 79%. Sixty-nine per cent of patients who obtained benefit received repeat treatment. Conclusions: Our findings suggest Dysport~R is a safe, well-tolerated and effective treatment for TMD and Masseteric hypertrophy.